zoledronic acid has been researched along with estramustine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Igawa, M; Kikuno, N; Nakamura, S; Shiina, H; Urakami, S | 1 |
| Tombal, B | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| Daignault, S; Dunn, RL; Escara-Wilke, J; Friedman, J; Ignatoski, KM; Keller, ET; Smith, DC; Zhang, X | 1 |
| Aoyama, M; Hirayama, Y; Ito, Y; Kanamaru, T; Kawamura, M; Nakamura, N; Sonoda, T | 1 |
| Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S | 1 |
| D'Amico, AV | 1 |
2 review(s) available for zoledronic acid and estramustine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Strategy in advanced castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
2 trial(s) available for zoledronic acid and estramustine
| Article | Year |
|---|---|
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2009 |
7 other study(ies) available for zoledronic acid and estramustine
| Article | Year |
|---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Bridged-Ring Compounds; Carboplatin; Dexamethasone; Diphosphonates; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Docetaxel and beyond.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |
[A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Diphosphonates; Estramustine; Fatal Outcome; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2011 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |